Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Zogenix, Inc. (ZGNX)

26.68   0 (0%) 09-24 16:41
Open: 26.6 Pre. Close: 26.68
High: 26.9 Low: 26.51
Volume: 11,252,392 Market Cap: 1,500(M)
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 26.96 - 27.1 27.1 - 27.2
Low: 26.14 - 26.32 26.32 - 26.47
Close: 26.43 - 26.7 26.7 - 26.92

Technical analysis

as of: 2022-09-23 4:28:54 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 31.24     One year: 31.41
Support: Support1: 26.51    Support2: 22.05
Resistance: Resistance1: 26.75    Resistance2: 26.89
Pivot: 26.68
Moving Average: MA(5): 26.68     MA(20): 26.68
MA(100): 26.68     MA(250): 23.01
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 43.5     %D(3): 43.5
RSI: RSI(14): 77.7
52-week: High: 26.89  Low: 11.02
Average Vol(K): 3-Month: 11,252 (K)  10-Days: 11,252 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ZGNX ] has closed Bollinger Bands are 0% narrower than normal.

Headline News

Mon, 27 Jun 2022
UCB Commences Tender Offer to Acquire Zogenix, Inc. - UCB

Mon, 07 Mar 2022
UCB Completes Acquisition of Zogenix, Inc. - PR Newswire

Fri, 04 Mar 2022
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022 - GlobeNewswire

Tue, 15 Feb 2022
Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases - GlobeNewswire

Tue, 01 Feb 2022
How did UCB close its $1.9B deal to buy Zogenix and its key epilepsy drug? SEC filing reveals details - FiercePharma

Fri, 21 Jan 2022
Why Zogenix Flew Higher Before Leveling Off This Week - The Motley Fool

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 56 (M)
Shares Float 49 (M)
% Held by Insiders 0.6 (%)
% Held by Institutions 107.2 (%)
Shares Short 5,890 (K)
Shares Short P.Month 6,540 (K)

Stock Financials

EPS -4.35
EPS Est Next Qtl -0.93
EPS Est This Year -3.62
EPS Est Next Year -3.46
Book Value (p.s.) 4.01
Profit Margin (%) 0
Operating Margin (%) -344
Return on Assets (ttm) -23
Return on Equity (ttm) -75.1
Qtrly Rev. Growth 690.5
Gross Profit (p.s.) -2.24
Sales Per Share 1.13
EBITDA (p.s.) -3.74
Qtrly Earnings Growth 0
Operating Cash Flow -182 (M)
Levered Free Cash Flow -97 (M)

Stock Valuations

PE Ratio -6.14
PEG Ratio 0
Price to Book value 6.65
Price to Sales 23.49
Price to Cash Flow -8.2

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.